Table 2 Mortality ratesa and relative indices of inequality related to education by cancer site among women, by population
All cancers | Lung | UADT | Leukaemia and Hodgkin's disease | Breast | Cervix | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MR | RII (95% CI) | MR | RII (95% CI) | MR | RII (95% CI) | MR | RII (95% CI) | MR | RII (95% CI) | MR | RII (95% CI) | |
Madrid | 242 | 0.89 (0.74–1.08) | 15 | 0.34 (0.17–0.65) | 5 | 1.02 (0.27–3.79) | 8 | 0.94 (0.34–2.62) | 48 | 0.51 (0.35–0.74) | 5 | 4.87 (0.92–25.90) |
Basque region | 178 | 0.63 (0.54–0.75) | 13 | 0.29 (0.17–0.48) | 4 | 0.76 (0.26–2.25) | 5 | 0.73 (0.28–1.92) | 36 | 0.61 (0.43–0.86) | 3 | 4.31 (0.79–23.49) |
Barcelona | 246 | 1.04 (0.94–1.16) | 16 | 0.49 (0.34–0.69) | 5 | 0.79 (0.40–1.56) | 8 | 1.20 (0.66–2.19) | 51 | 0.79 (0.64–0.97) | 5 | 1.43 (0.71–2.91) |
Slovenia | 302 | 0.93 (0.87–1.00) | 29 | 0.49 (0.40–0.61) | 5 | 1.56 (0.89–2.74) | 8 | 0.73 (0.48–1.10) | 57 | 0.69 (0.59–0.80) | 9 | 2.10 (1.39–3.17) |
Turin | 284 | 1.12 (0.98–1.27) | 32 | 0.74 (0.52–1.06) | 6 | 1.16 (0.49–2.77) | 10 | 0.95 (0.49–1.82) | 61 | 0.93 (0.72–1.20) | 3 | 7.77 (1.48–40.86) |
Switzerland | 263 | 1.21 (1.16–1.26) | 29 | 1.35 (1.20–1.52) | 7 | 1.28 (1.00–1.63) | 8 | 1.05 (0.84–1.31) | 59 | 0.96 (0.88–1.04) | 5 | 1.78 (1.33–2.38) |
France | 239 | 1.30 (1.08–1.57) | 18 | 0.84 (0.45–1.55) | 7 | 4.41 (1.38–14.08) | 8 | 0.87 (0.31–2.48) | 54 | 1.19 (0.82–1.71) | 4 | 3.05 (0.65–14.45) |
Belgium | 276 | 1.17 (1.11–1.23) | 26 | 1.61 (1.35–1.93) | 7 | 0.88 (0.64–1.20) | 9 | 1.10 (0.82–1.47) | 66 | 0.83 (0.75–0.91) | 5 | 2.36 (1.58–3.51) |
Denmark | 356 | 1.33 (1.26–1.40) | 80 | 2.31 (2.05–2.60) | 11 | 1.60 (1.17–2.19) | 8 | 1.09 (0.77–1.55) | 67 | 0.83 (0.74–0.93) | 9 | 2.26 (1.61–3.16) |
Norway | 303 | 1.38 (1.32–1.44) | 43 | 2.77 (2.45–3.14) | 6 | 1.94 (1.40–2.69) | 7 | 0.89 (0.66–1.19) | 51 | 0.78 (0.70–0.86) | 9 | 3.28 (2.52–4.27) |
Sweden | 271 | 1.31 (1.27–1.35) | 37 | 1.79 (1.63–1.96) | 5 | 1.70 (1.33–2.17) | 8 | 0.98 (0.81–1.18) | 45 | 0.88 (0.82–0.95) | 5 | 2.59 (2.02–3.32) |
Finland | 257 | 1.20 (1.15–1.26) | 24 | 1.85 (1.56–2.21) | 6 | 2.00 (1.41–2.82) | 9 | 1.10 (0.84–1.44) | 46 | 0.85 (0.76–0.94) | 4 | 3.47 (2.20–5.46) |
Interactionb | <0.005 | <0.005 | <0.005 | NS | NS | NS | ||||||
Stomach | Liver | Kidney and bladder | Pancreas | Colorectum | Other | |||||||
MR | RII (95% CI) | MR | RII (95% CI) | MR | RII (95% CI) | MR | RII (95% CI) | MR | RII (95% CI) | MR | RII (95% CI) | |
Madrid | 17 | 2.41 (0.97–5.97) | 12 | 0.68 (0.27–1.68) | 6 | 0.64 (0.18–2.26) | 12 | 0.73 (0.31–1.74) | 32 | 1.19 (0.67–2.10) | 83 | 1.29 (0.91–1.83) |
Basque region | 11 | 1.80 (0.76–4.24) | 7 | 1.29 (0.43–3.89) | 6 | 0.54 (0.21–1.40) | 10 | 0.38 (0.19–0.75) | 20 | 0.77 (0.44–1.33) | 62 | 0.63 (0.47–0.85) |
Barcelona | 11 | 2.02 (1.17–3.50) | 12 | 1.63 (0.97–2.76) | 6 | 1.26 (0.64–2.47) | 11 | 0.67 (0.43–1.05) | 32 | 1.36 (1.00–1.84) | 74 | 1.30 (1.07–1.57) |
Slovenia | 24 | 1.51 (1.15–1.99) | 7 | 1.55 (0.93–2.59) | 9 | 0.64 (0.42–0.96) | 16 | 0.86 (0.63–1.18) | 38 | 1.28 (1.03–1.59) | 100 | 1.04 (0.92–1.18) |
Turin | 13 | 3.16 (1.48–6.71) | 10 | 2.77 (1.16–6.59) | 8 | 2.52 (0.94–6.75) | 15 | 1.25 (0.69–2.24) | 34 | 0.97 (0.67–1.41) | 93 | 1.17 (0.94–1.47) |
Switzerland | 9 | 2.34 (1.86–2.95) | 5 | 1.49 (1.10–2.03) | 11 | 1.89 (1.54–2.32) | 16 | 1.27 (1.08–1.50) | 26 | 1.02 (0.90–1.16) | 89 | 1.23 (1.15–1.32) |
France | 8 | 4.95 (1.24–19.68) | 6 | 1.59 (0.45–5.63) | 8 | 0.96 (0.35–2.64) | 12 | 1.86 (0.73–4.70) | 27 | 1.24 (0.70–2.17) | 86 | 1.26 (0.93–1.72) |
Belgium | 10 | 2.44 (1.74–3.41) | 5 | 1.38 (0.90–2.11) | 11 | 1.68 (1.24–2.28) | 13 | 1.31 (1.01–1.70) | 34 | 1.24 (1.05–1.45) | 90 | 1.22 (1.11–1.34) |
Denmark | 7 | 1.51 (1.01–2.25) | 5 | 1.72 (1.10–2.70) | 14 | 1.80 (1.35–2.40) | 17 | 0.94 (0.74–1.19) | 40 | 1.18 (1.01–1.39) | 100 | 1.23 (1.12–1.36) |
Norway | 12 | 1.77 (1.41–2.20) | 2 | 1.32 (0.79–2.18) | 12 | 2.09 (1.66–2.62) | 18 | 1.39 (1.16–1.67) | 42 | 1.25 (1.11–1.41) | 100 | 1.26 (1.17–1.36) |
Sweden | 9 | 1.83 (1.53–2.20) | 7 | 1.80 (1.45–2.24) | 12 | 1.71 (1.46–2.01) | 19 | 1.23 (1.09–1.39) | 29 | 1.31 (1.18–1.45) | 96 | 1.29 (1.22–1.37) |
Finland | 14 | 1.39 (1.12–1.73) | 7 | 1.81 (1.31–2.50) | 10 | 1.10 (0.85–1.41) | 20 | 1.45 (1.20–1.75) | 24 | 1.03 (0.88–1.21) | 93 | 1.21 (1.12–1.32) |
Interactionb | NS | NS | <0.005 | <0.005 | NS | <0.005 | ||||||
